NASDAQ:VERA Vera Therapeutics Q3 2024 Earnings Results & Report $26.79 -0.93 (-3.35%) Closing price 04:00 PM EasternExtended Trading$26.77 -0.02 (-0.07%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Vera Therapeutics missed analyst earnings expectations in its Q3 2024 results, released November 7, 2024. The company reported EPS of -$0.85 versus the -$0.64 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateNovember 7, 2024TimeBefore Market OpensConference Call8:00 AM ET Vera Therapeutics EPS ResultsActual EPS-$0.85Consensus EPS -$0.64Beat/MissMissed by -$0.21One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersVera Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsVera Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vera Therapeutics Q3 2024 Earnings FAQ Did Vera Therapeutics beat earnings estimates for Q3 2024? Vera Therapeutics (NASDAQ:VERA) reported earnings of -$0.85 per share for Q3 2024, missing the consensus estimate of -$0.64. The report was announced on Thursday, November 7, 2024. When is Vera Therapeutics' next earnings date? Vera Therapeutics' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Vera Therapeutics on the company's earnings history page. Vera Therapeutics Earnings HeadlinesLeerink Partners initiates coverage of Vera Therapeutics at market perform3 hours ago | msn.comLeerink Partners Initiates Vera Therapeutics at Market Perform With $34 Price Target3 hours ago | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 13 at 1:00 AM | Weiss Ratings (Ad)Vera Therapeutics (NASDAQ:VERA) Now Covered by Leerink PartnersOctober 12 at 8:42 AM | americanbankingnews.comBofA Securities Adjusts Vera Therapeutics Price Target to $60 From $66, Maintains Buy RatingOctober 9, 2026 | finance.yahoo.comVera Therapeutics, Inc. (NASDAQ:VERA) Stock Has Consensus Target Price of $80.15October 8, 2026 | americanbankingnews.comSee More Vera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email. Email Address About Vera TherapeuticsVera Therapeutics (NASDAQ:VERA) is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s lead product candidate is atacicept, an investigational fusion protein designed to inhibit two immune signaling molecules, B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which contribute to the survival and activity of antibody-producing B cells. Vera is primarily studying atacicept as a potential treatment for immunoglobulin A nephropathy (IgA nephropathy), a chronic kidney disorder caused by the buildup of IgA immune complexes. The company has also evaluated the therapy in other autoimmune conditions, including systemic lupus erythematosus and multiple sclerosis. Atacicept remains an investigational product and has not been approved for commercial use. Founded in 2016 and headquartered in South San Francisco, California, Vera conducts its research and clinical development activities through international studies involving patients and medical centers in multiple regions. The company was founded by Marshall Fordyce, who has served as its chief executive officer. Vera Therapeutics is listed on the Nasdaq Stock Market under the symbol VERA.View Vera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
